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Abstract 
The aims of this thesis were to examine: ( 1) plasma and cellular pharmacokinetics 
of daunorubicin and its major metabolite daunorubicinol in patients with acute leukaemia, 
and the relationships between pharmacokinetics, patient response and the presence of P 
glycoprotein; (2) actions of the multidrug resistance reversing agents cyclosporin A and 
trifluoperazine, at clinically achievable concentrations, on daunorubicin accumulation and 
retention in human leukaemia cell lines and patients with acute leukaemia; and (3) effect 
of daunorubicin on the cell membrane of both sensitive and resistant cell lines, with and 
without the multidrug resistance reversing agents. 
Twenty-seven patients with acute leukaemia received daunorubicin as part of 
induction therapy. The plasma and cellular levels of daunorubicin and its metabolite 
daunorubicinol were determined using HPLC. There were no significant differences 
between patients who went into complete remission (12/23) compared to those who did not 
respond for any of the plasma pharrnacokinetic parameters. There was a significant 
difference in the cellular daunorubicin and daunorubicinol area under the concentration-
time curve between responders and non responders (p < 0.02), as well as in cellular Cmax, 
cellular clearance and cellular volume of distribution. Eleven patients were P glycoprotein 
positive and 10 P glycoprotein negative (no sample available for 2 patients). There was no 
correlation between patient response and the presence of P glycoprotein; nor a correlation 
between the cellular concentration of daunorubicin or daunorubicinol and P glycoprotein. 
Patients responding to chemotherapy had higher cellular daunorubicin and daunorubicinol 
compared to non responders. In contrast to in vitro studies, overexpression ofP glycoprotein 
was not the reason for the lower cellular daunorubicin levels. 
Cyclosporin A was capable of increasing both cellular accumulation and 
retention in the drug resistant CEM!VLB and HL 60/ADR cell lines, but not in the drug 
sensitive CEM and HL 60 cell lines. Trifluoperazine had no effect in any of the four cell 
lines. In contrast to the cell line findings, only the combination of cyclosporin A and 
trifluoperazine were able to increase both accumulation and retention in the blast cells of 
patients at initial presentation. The multidrug resistant reversing agents alone had no effect 
in increasing accumulation or retention in the blast cells of P glycoprotein positive patients, 
nor patients in relapse. The cell line studies show that at clinically relevant concentrations 
only cyclosporin A is capable of increasing daunorubicin accumulation in both the drug 
resistant P glycoprotein positive (VLB) and P glycoprotein negative (ADR) cell lines. Thus, 
cyclosporin A does not work only by inhibiting the actions ofP glycoprotein. Trifluoperazine 
was unable to reverse drug resistance at clinically relevant concentrations in either cell lines 
or patient blast cells. However, the combination of cyclosporin A and trifluoperazine 
increased accumulation in patient blast cells at initial presentation, suggesting that these 
agents may be more useful in patients at initial presentation than relapse. 
Daunorubicin was immobilised by linking it to poly vinyl alcohol and the effect 
of irnrnobilised-daunorubicin was studied on the four cell lines above. The immobilised-
daunorubicin was able to decrease cell growth in the drug sensitive HL 60 cell line but not 
in the drug resistant VLB or ADR cell lines. Poly vinyl alcohol itself was cytotoxic to the 
CEM cell line. The multidrug resistance reversing agents cyclosporin A and trifluoperazine 
were only capable of increasing cytotoxicity in the HL 60 cell line, with no effect in the drug 
resistant VLB or ADR cell lines. 
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